One of the trials was conducted on 44 volunteers who were given either BGG’s saw palmetto or a placebo over an eight-week period (1). The treatment group experienced a statistically significant reduction in urinary issues versus the placebo group.
The second trial established safety at six times the recommended dosage (2).
Related: BAPP Publishes Lab Guidance Doc on Saw Palmetto Extract Healthy and Vibrant — At Every Age Optimizing Urological Health
“We are extremely pleased to offer a saw palmetto extract that has been proven efficacious and safe through peer-reviewed human research," Yanmei Li, Ph.D., BGG’s chief scientific officer, said in a press release. "BGG prides itself not only on producing products with industry-leading quality, but also on sponsoring clinical research to validate our products’ ability to positively affect consumers’ health. This combination of top quality and clinical validation has been extremely well-received by leading brands in the market for our other products, and we look forward to similar success in the saw palmetto category.”The trials:
- Sekikawa, T. Kizawa, Y. Li, Y. Miura, N. (2019). “A clinical study for evaluating the safety of excessive consumption of saw palmetto extract.” Japanese Pharmacology and Therapeutics. 47. 445-452.
- Kushima, M. Okamoto, K. Kizawa, Y. Sekikawa, T. Li, Y. Takara, T. (2018) “A Verification Study on the Improvement of Urination Issues with Ingestion of Saw Palmetto Fruit Extract: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study.” Pharmacometrics 95(5/6): 101-111, 2018.
